About Michael Tusche

Michael Tusche, Ph.D. MBA serves as a Co-Chief Executive Officer of Treadwell Therapeutics.

Dr. Michael Tusche brings over a decade of experience as a scientist, investor, and entrepreneur to his role of co-CEO of Treadwell Therapeutics. Previously, Michael was the Chief Scientific Officer and Co-Founder of Nirsum Laboratories, Inc., a startup

biotechnology company developing small molecule therapeutics for Neuroscience indications. At Nirsum, Dr. Tusche was the Co-inventor of the company’s foundational Intellectual Property and a Principal Investigator of an NIH/NIDA grant, funding the company’s operations into mid-stage clinical studies. Prior to Nirsum, Michael was the Senior Biotechnology Analyst at Mountain Brook Capital Management, LLC, a Healthcare focused Long/Short equity only Hedge Fund, where his focus was Investments in publicly listed Biopharmaceutical companies. Before Mountain Brook, Dr. Tusche was an Associate at MLV and Co., a boutique investment bank with a focus on capital raising and advisory work for Life Science-based companies. Dr. Tusche also led Biologic drug discovery at the Campbell Family Institute in Toronto, Canada, where he managed a multidisciplinary R&D team in the pre-clinical development and validation of novel drug candidates. Michael started his career as a Scientist in drug discovery at Bayer AG in Japan, where he worked on early-stage development of small molecule GPCR antagonists for allergic and inflammatory diseases.

Dr. Tusche received his B.Sc. (with Distinction) in Biochemistry from the University of Victoria. He also received a Ph.D. in Immunology from the University of Toronto where he trained in the laboratory of Dr. Tak Mak. Michael received his M.B.A. from the University of Toronto. He is a co-author on several peer-reviewed publications, the recipient of numerous scientific and business awards, and named inventor on issued US patents focusing on small molecule and biologic therapeutics.